64 related articles for article (PubMed ID: 25573967)
1. TET2 loss, a rescue of JAK2V617F HSCs.
Vainchenker W; Plo I
Blood; 2015 Jan; 125(2):212-3. PubMed ID: 25573967
[TBL] [Abstract][Full Text] [Related]
2. Effect of mutation order on myeloproliferative neoplasms.
Ortmann CA; Kent DG; Nangalia J; Silber Y; Wedge DC; Grinfeld J; Baxter EJ; Massie CE; Papaemmanuil E; Menon S; Godfrey AL; Dimitropoulou D; Guglielmelli P; Bellosillo B; Besses C; Döhner K; Harrison CN; Vassiliou GS; Vannucchi A; Campbell PJ; Green AR
N Engl J Med; 2015 Feb; 372(7):601-612. PubMed ID: 25671252
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of TET protein-mediated DNA demethylation and its role in the regulation of mouse development.
Jia ZW; Gao SX; Zhang YC; Zhang XH
Yi Chuan; 2015 Jan; 37(1):34-40. PubMed ID: 25608811
[TBL] [Abstract][Full Text] [Related]
4. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation.
Wang Y; Xiao M; Chen X; Chen L; Xu Y; Lv L; Wang P; Yang H; Ma S; Lin H; Jiao B; Ren R; Ye D; Guan KL; Xiong Y
Mol Cell; 2015 Feb; 57(4):662-673. PubMed ID: 25601757
[TBL] [Abstract][Full Text] [Related]
5. Dynamic switching of active promoter and enhancer domains regulates Tet1 and Tet2 expression during cell state transitions between pluripotency and differentiation.
Sohni A; Bartoccetti M; Khoueiry R; Spans L; Vande Velde J; De Troyer L; Pulakanti K; Claessens F; Rao S; Koh KP
Mol Cell Biol; 2015 Mar; 35(6):1026-42. PubMed ID: 25582196
[TBL] [Abstract][Full Text] [Related]
6. A CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm.
Cabagnols X; Cayuela JM; Vainchenker W
N Engl J Med; 2015 Feb; 372(7):688-90. PubMed ID: 25671272
[No Abstract] [Full Text] [Related]
7. Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN.
Grisouard J; Shimizu T; Duek A; Kubovcakova L; Hao-Shen H; Dirnhofer S; Skoda RC
Blood; 2015 Mar; 125(13):2131-40. PubMed ID: 25595737
[TBL] [Abstract][Full Text] [Related]
8. Cancer evolution constrained by mutation order.
Swanton C
N Engl J Med; 2015 Feb; 372(7):661-3. PubMed ID: 25671259
[No Abstract] [Full Text] [Related]
9. The evolving genomic landscape of myeloproliferative neoplasms.
Nangalia J; Green TR
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):287-96. PubMed ID: 25696868
[TBL] [Abstract][Full Text] [Related]
10. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
11. Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.
Mascarenhas J
Leuk Lymphoma; 2015; 56(9):2493-7. PubMed ID: 25586607
[TBL] [Abstract][Full Text] [Related]
12. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?
Chen E; Mullally A
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):268-76. PubMed ID: 25696866
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic regulation in human melanoma: past and future.
Sarkar D; Leung EY; Baguley BC; Finlay GJ; Askarian-Amiri ME
Epigenetics; 2015; 10(2):103-21. PubMed ID: 25587943
[TBL] [Abstract][Full Text] [Related]
14. Making sense of hematopoietic stem cell niches.
Boulais PE; Frenette PS
Blood; 2015 Apr; 125(17):2621-9. PubMed ID: 25762174
[TBL] [Abstract][Full Text] [Related]
15. A new path to leukemia with WIT.
Sardina JL; Graf T
Mol Cell; 2015 Feb; 57(4):573-574. PubMed ID: 25699704
[TBL] [Abstract][Full Text] [Related]
16. TET proteins and the control of cytosine demethylation in cancer.
Scourzic L; Mouly E; Bernard OA
Genome Med; 2015; 7(1):9. PubMed ID: 25632305
[TBL] [Abstract][Full Text] [Related]
17. Haploinsufficiency, but not defective paternal 5mC oxidation, accounts for the developmental defects of maternal Tet3 knockouts.
Inoue A; Shen L; Matoba S; Zhang Y
Cell Rep; 2015 Feb; 10(4):463-70. PubMed ID: 25640176
[TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular genetic characterization of myelofibrosis.
Hobbs GS; Rampal RK
Curr Opin Hematol; 2015 Mar; 22(2):177-83. PubMed ID: 25635755
[TBL] [Abstract][Full Text] [Related]
19. Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis.
Zamora L; Xicoy B; Cabezón M; Fernandez C; Marcé S; Velez P; Xandri M; Gallardo D; Millá F; Feliu E; Boqué C
Leuk Lymphoma; 2015; 56(10):2973-4. PubMed ID: 25686645
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
